Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention
In an avian flu pandemic, which drugs could be used to treat or prevent infection with influenza A (H5N1) virus? Foremost are the viral neuraminidase inhibitors oseltamivir and zanamivir, which have already been used to treat human influenza A (H1N1 and H3N2) and B virus infections. The use of the M...
Published in: | Trends in Pharmacological Sciences |
---|---|
Main Authors: | , |
Format: | Text |
Language: | English |
Published: |
Elsevier Ltd.
2007
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112898/ http://www.ncbi.nlm.nih.gov/pubmed/17481739 https://doi.org/10.1016/j.tips.2007.04.005 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:7112898 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:7112898 2023-05-15T15:34:16+02:00 Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention De Clercq, Erik Neyts, Johan 2007-06 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112898/ http://www.ncbi.nlm.nih.gov/pubmed/17481739 https://doi.org/10.1016/j.tips.2007.04.005 en eng Elsevier Ltd. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112898/ http://www.ncbi.nlm.nih.gov/pubmed/17481739 http://dx.doi.org/10.1016/j.tips.2007.04.005 Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Article Text 2007 ftpubmed https://doi.org/10.1016/j.tips.2007.04.005 2020-04-05T00:59:23Z In an avian flu pandemic, which drugs could be used to treat or prevent infection with influenza A (H5N1) virus? Foremost are the viral neuraminidase inhibitors oseltamivir and zanamivir, which have already been used to treat human influenza A (H1N1 and H3N2) and B virus infections. The use of the M2 ion channel blockers amantadine and rimantadine is compounded by the rapid development of drug resistance. Although formally approved for other indications (i.e. treatment of hepatitis C), ribavirin and pegylated interferon might also be useful for controlling avian flu. Combined use of the currently available drugs should be taken into account and attempts should be made to develop new strategies directed at unexplored targets such as the viral proteins hemagglutinin, the viral polymerase (and endonuclease) and the non-structural protein NS1. As has been shown for other viral infections, RNA interference could be a powerful means with which to suppress the replication of avian H5N1. Text Avian flu PubMed Central (PMC) Trends in Pharmacological Sciences 28 6 280 285 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Article |
spellingShingle |
Article De Clercq, Erik Neyts, Johan Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention |
topic_facet |
Article |
description |
In an avian flu pandemic, which drugs could be used to treat or prevent infection with influenza A (H5N1) virus? Foremost are the viral neuraminidase inhibitors oseltamivir and zanamivir, which have already been used to treat human influenza A (H1N1 and H3N2) and B virus infections. The use of the M2 ion channel blockers amantadine and rimantadine is compounded by the rapid development of drug resistance. Although formally approved for other indications (i.e. treatment of hepatitis C), ribavirin and pegylated interferon might also be useful for controlling avian flu. Combined use of the currently available drugs should be taken into account and attempts should be made to develop new strategies directed at unexplored targets such as the viral proteins hemagglutinin, the viral polymerase (and endonuclease) and the non-structural protein NS1. As has been shown for other viral infections, RNA interference could be a powerful means with which to suppress the replication of avian H5N1. |
format |
Text |
author |
De Clercq, Erik Neyts, Johan |
author_facet |
De Clercq, Erik Neyts, Johan |
author_sort |
De Clercq, Erik |
title |
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention |
title_short |
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention |
title_full |
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention |
title_fullStr |
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention |
title_full_unstemmed |
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention |
title_sort |
avian influenza a (h5n1) infection: targets and strategies for chemotherapeutic intervention |
publisher |
Elsevier Ltd. |
publishDate |
2007 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112898/ http://www.ncbi.nlm.nih.gov/pubmed/17481739 https://doi.org/10.1016/j.tips.2007.04.005 |
genre |
Avian flu |
genre_facet |
Avian flu |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112898/ http://www.ncbi.nlm.nih.gov/pubmed/17481739 http://dx.doi.org/10.1016/j.tips.2007.04.005 |
op_rights |
Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
op_doi |
https://doi.org/10.1016/j.tips.2007.04.005 |
container_title |
Trends in Pharmacological Sciences |
container_volume |
28 |
container_issue |
6 |
container_start_page |
280 |
op_container_end_page |
285 |
_version_ |
1766364723171819520 |